Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine

AIDS

Volumn 19, Issue 2, 2005, Pages 213-215

  León, Agathe ^a   Martinez, Esteban ^a   Mallolas, Josep ^a   Laguno, Montserrat ^a   Blanco, Jose Luis ^a   Pumarola, Tomás ^a   Gatell, Josep María ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; AGED; ARTICLE; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 15744384550     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200501280-00017     Document Type: Article

References (9)

1. Gulick RM, Ribaudo HJ, Shimuka CM, Lustgartens, Meyer WA, Klingman K, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-1861.
2. Wainberg MA, Turner D. Resistance issues with new nucleoside/nucfeotide backbone options. J Acquir Immune Defic Syndr 2004; 37:S36-S43.
3. Kaul S, Damle B, Bassi K, Xie J, Gale J, Ryan K, et al. Pharmacokinetic evaluation of reduced doses of didanosine enteric coated capsules (didanosine-EC) in combination with tenofovir disoproxil fumarate (TDF) and food for a once-daily antiretroviral regimen. Presented at: 4th International Workshop on Clinical Pharmacology of HIV Therapy. Cannes, March 2003 [Abstract 8.1].
4. D'Aquila RT, Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, et al. Drug resistance mutations in HIV-1. Topics HIV Med 2003; 11:92-96.
5. Petropoulos CJ. High-level resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) in the absence of known resistance mutations. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, September 2003 [Abstract H-451].
6. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. Presented at: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [Abstract 51].
7. Podzamczer D, Ferrer E, Gatell JM, Niubo J, Dalmau D, Leon A, et al. Early virologic failure and occurrence of resistance in naive patients receiving tenofovir, didanosine and efavirenz. Presented at: XIIIth International HIV Drug Resistance Workshop. Tenerife, June 2004 [Abstract 156].
8. Negredo E, Moltó J, Burger D, Viciana P, Ribera E, Paredes R, et al. Unexpected CD4 cell-count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 2004; 18:459-463.
9. Martinez E, Milinkovic A, De Lazzari E, Ravasi G, Blanco JL, Larrousse M, et al. Pancreatic toxic effects associated with coadministration of didanosine and tenofovir in HIV-infected adults. Lancet 2004; 364:8-10.